| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Fulcrum Therapeutics, Inc.$3.73
+0.01 (+0.27%)
D 33Pipeline Score Overvalued Pharma · Clinical
Market Cap
437.78 M
EPS
-1.15
P/E Ratio
-
Value Trade
17.82 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
14.08 M
Operating CF
-18.75 M
Total Assets
346.77 M
Total Liabilities
13.47 M
Equity
333.30 M
D/E Ratio
12,345
-5.87 %
Week
-13.32 %
1 Month
-43.31 %
3 Month
-40.27 %
6 Month
-34.43 %
5 Year
-54.69 %
All Time
Cash Data
Cash Position
333.32 M
Monthly Burn
6.25 M
Runway
50.3 mo
Burn Trend
SEC Filing
Apr 27, 2026
Overview
Volume
589.76 K
52 Week Range
5.88 - 15.74
% held by Insiders
15.3 %
% held by Institutions
114.13 %
Enterprise Value
110.33 M
Total Shares
66.64 M
Short %
11.25 %
Float Shares
61.44 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Fulcrum Therapeutics, Inc.
388Total events
4Upcoming
53Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
◆Trial InitiationPociredirTrial
Subscribe to view catalyst details
TBD
▼Program DiscontinuationPociredirCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | pociredir | Phase 1b data readout | Phase 1b | — | – | – | – |
2026-06-30 | pociredir | Phase 1b data readout | Phase 1b | — | – | – | – |
2026-06-30 | pociredir | Phase 1b data readout | Phase 1b | — | – | – | – |
Drug Pipeline Intelligence
D33
Pipeline Score $160M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.4x
rNPV / MCap Top 45%
Micro Cap (rank 503 of 913)
Percentile RankFulcrum Therapeutics, Inc. faces pipeline headwinds (33/100), with $401M risk-adjusted pipeline value, led by Pociredir in Sickle Cell Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pociredir Small molecule | Sickle Cell Disease | Phase 2 | NCT05169580 | 41% | $176M | COMPLETED | 95 | - | - | Jan 20, 2026 | ELEVATED_RISK | Feb 12, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
pociredir Fast TrackOrphan | sickle cell disease | Phase 1b | 2026-02-24 | mean absolute hb F increase: 12.2%; baseline hb F: 7.1%; week 12 hb F: 19.3% Read More | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 Read More | |
pociredir Fast TrackOrphan | sickle cell disease | Phase 1b | 2026-02-24 | mean absolute hb F increase: 12.2%; baseline hb F: 7.1%; week 12 hb F: 19.3% Read More | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 Read More | |
pociredir Fast TrackOrphan | sickle cell disease | Phase 1b | 2026-02-24 | mean absolute hb F increase: 12.2%; baseline hb F: 7.1%; week 12 hb F: 19.3% Read More | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FULC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
FULC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
FULC▼ -51.1%on this news
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
Fulcrum Therapeutics has announced the discontinuation of its pociredir program for sickle cell disease following FDA feedback regarding safety concerns. The decision was influenced by the observed risk of secondary malignancies linked to similar treatments. The company will now explore strategic alternatives to enhance stockholder value while managing its operating expenses.
Read more →FULC▼ -51.1%on this newsshared move
Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
Fulcrum Therapeutics has halted the development of its sickle cell disease drug pociredir, following FDA feedback that highlighted malignancy risks associated with therapies targeting the PRC2 complex. The company disclosed that there is 'no viable regulatory path forward' for pociredir. In response to the stock's sharp decline due to this news, Johnson Fistel, PLLP is investigating whether Fulcrum and certain executives violated federal securities laws potentially affecting investors. Shareholders are encouraged to reach out for more information about recovering losses.
Read more →FULC▼ -7.2%on this news· ran to -55% by day 1shared move
Fast Track and Orphan Drug Designation from the FDA for the treatment of SCD. To learn more about clinical trials of pociredir please visit ClinicalTrials.gov. About Sickle Cell Disease SCD is a genetic disorder of the r
Fulcrum Therapeutics has announced the discontinuation of its pociredir program for sickle cell disease (SCD) following FDA feedback related to safety concerns. These concerns stem from secondary malignancies observed with a similar drug, Tazverik, which led to regulatory challenges for pociredir. Despite earlier promising results in increasing fetal hemoglobin levels, the FDA concluded there is no viable path forward for clinical development. In light of this, the company will review strategic alternatives to enhance shareholder value while managing operational costs.
Read more →FULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics has granted non-statutory stock options to two new employees as part of its 2022 Inducement Stock Incentive Plan. A total of 55,500 options were issued at an exercise price equivalent to the closing stock price on May 4, 2026. These options will vest over a four-year period, showcasing the company's approach to incentivizing new talent in line with Nasdaq Listing Rule 5635(c)(4). This move indicates the company's ongoing commitment to its operational growth.
Read more →FULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
Fulcrum Therapeutics reported positive clinical data for pociredir, indicating significant fetal hemoglobin induction and improvements in anemia markers. The company plans to initiate a registration-enabling trial in late 2026 and has dosed the first patient in a long-term safety trial. Fulcrum's financial position remains strong with $333.3 million in cash, extending its runway into 2029.
Read more →FULCFulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
Fulcrum Therapeutics has appointed Dr. Josh Lehrer to its Board of Directors. Dr. Lehrer, a physician-scientist with over 20 years of experience, previously led the development of Oxbryta for sickle cell disease. His expertise is expected to enhance Fulcrum's efforts in advancing pociredir and its hematology pipeline.
Read more →FULCFulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
Fulcrum Therapeutics has announced the release of its first quarter 2026 financial results, scheduled for April 27, 2026. A conference call and webcast will be held at 8:00 a.m. ET to discuss these results and provide updates on recent corporate developments. Interested participants can register online to access the call.
Read more →FULCFulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics will present at the Leerink Partners Global Healthcare Conference on March 10, 2025. The presentation will focus on their clinical-stage programs aimed at treating genetically defined rare diseases. A webcast of the event will be available, along with a replay for 30 days post-presentation.
Read more →FULC▼ -21.2%on this news
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
Fulcrum Therapeutics reported positive results from the 20 mg cohort of the Phase 1b PIONEER trial for pociredir, showing significant increases in fetal hemoglobin levels. The company plans to initiate a registration-enabling trial in late 2026 and ended 2025 with a strong cash position, ensuring funding through 2029. However, the company also reported a substantial net loss for the year.
Read more →FULC▼ -21.2%on this newsshared move
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics reported promising 12-week results from the 20 mg dose cohort of its Phase 1b PIONEER trial for pociredir in treating sickle cell disease. The study showed a 12.2% increase in fetal hemoglobin levels, with 58% of patients achieving HbF levels of 20% or higher. Pociredir was well-tolerated, and the company plans to initiate a registration-enabling trial in late 2026.
Read more →FULCFulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics will present results from the 20 mg dose cohort of the Phase 1b PIONEER trial for pociredir, an investigational treatment for sickle cell disease. The conference call is scheduled for February 24, 2026, and will feature insights from Dr. Martin Steinberg. Pociredir has demonstrated positive effects on fetal hemoglobin levels and has received FDA designations.
Read more →FULC▲ +5%on this news
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2026
Fulcrum Therapeutics announced the grant of 70,000 stock options to a new employee as part of its 2022 Inducement Stock Incentive Plan. The options, priced at $10.72 per share, will vest over four years, reflecting the company's strategy to attract and retain talent. This move aligns with Fulcrum's focus on developing therapies for genetically defined rare diseases.
Read more →FULCJanuary 2026 Disclaimer and Notice This presentation contains “forward-looking statements” of Fulcrum Therapeutics, Inc. (Fulcrum or Fulcrum Therapeutics) within the meaning of the Private Securities Litiga
Fulcrum Therapeutics presented promising forward-looking statements regarding its blood disease treatment, pociredir, which is aimed at enhancing fetal hemoglobin production in sickle cell disease (SCD) patients. The data from initial cohorts show robust hemoglobin improvements and received designations favoring its regulatory review. However, the company acknowledges that clinical uncertainties and ongoing risks must be carefully managed as the therapy progresses through trials and regulatory pathways. Additionally, Fulcrum's financial outlook appears stable, extending cash runway into 2029.
Read more →FULCFulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Fulcrum Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will highlight their focus on developing small molecules for genetically defined rare diseases, particularly their lead program aimed at treating sickle cell disease. A live webcast will be available for those interested in the presentation.
Read more →FULC▼ -5.5%on this news
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Fulcrum Therapeutics announced the pricing of an upsized public offering to sell 11,851,853 shares of common stock at $13.50 per share, alongside pre-funded warrants for $13.499 each. The total anticipated proceeds from the offering are around $175 million, which will support various corporate activities, particularly research and development. The offering, managed by notable financial institutions, is subject to customary closing conditions and is expected to finalize soon.
Read more →FULC▲ +46%on this news· ran to +64% by day 1shared move
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Fulcrum Therapeutics announced positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease. The trial showed a significant increase in fetal hemoglobin levels, with 58% of patients achieving levels of 20% or higher. Pociredir was well-tolerated, with no serious adverse events reported. The company plans to provide further updates in Q1 2026.
Read more →FULC▲ +46%on this news· ran to +64% by day 1shared move
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
Fulcrum Therapeutics has granted non-statutory stock options to a new employee as part of its 2022 Inducement Stock Incentive Plan. The grant includes 5,250 options with an exercise price of $9.87 per share, vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to grow its team.
Read more →FULC▲ +46%on this news· ran to +64% by day 1shared move
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
Fulcrum Therapeutics has announced a proposed public offering to raise $150 million through the sale of its common stock. The company plans to utilize the proceeds for general corporate purposes, including research and development and potential acquisitions. The offering is contingent on market conditions, and it includes an option for underwriters to purchase additional shares. Fulcrum is focused on developing treatments for genetically defined rare diseases, enhancing investor prospects depending on the development of its lead programs.
Read more →FULCFulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
Fulcrum Therapeutics will host an investor event on December 7, 2025, to present new clinical data from the Phase 1b PIONEER trial of pociredir for sickle cell disease. The event will feature insights from key medical experts and will also be presented at the 67th ASH Annual Meeting. Pociredir has shown promise in increasing fetal hemoglobin levels in patients.
Read more →FULC▼ -7.2%on this newsshared move
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Fulcrum Therapeutics announced that new clinical data from the Phase 1b PIONEER trial of pociredir in sickle cell disease will be presented at the 67th ASH Annual Meeting. The presentation will include data from the 12 mg and 20 mg cohorts, showcasing pociredir's potential as a disease-modifying therapy. Additionally, Fulcrum will highlight preclinical data on its calmodulin pathway modulator program.
Read more →FULC▼ -6.4%on this newsshared move
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
Fulcrum Therapeutics reported positive results from the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir, aimed at treating sickle cell disease. The company has completed enrollment in the 20 mg dose cohort and expects to share results by year-end 2025. Fulcrum ended Q3 2025 with $200.6 million in cash, ensuring operational funding through 2028.
Read more →FULC▼ -6.8%on this news
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
Fulcrum Therapeutics will release its third quarter 2025 financial results on October 29, 2025. A conference call and webcast will follow at 8:00 a.m. ET to discuss these results and recent corporate developments. The company focuses on developing small molecules for genetically defined rare diseases, particularly sickle cell disease.
Read more →FULCFulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
Fulcrum Therapeutics announced it will present preclinical data for FTX-6274, an EED inhibitor, at the ESMO Congress 2025. The data suggests potential efficacy in treating castration-resistant prostate cancer. The presentation is scheduled for October 18, 2025, in Berlin, Germany. Fulcrum is exploring partnerships to advance this oncology candidate.
Read more →FULCAugust 2025 Disclaimer and Notice This presentation contains “forward-looking statements” of Fulcrum Therapeutics, Inc. (Fulcrum or Fulcrum Therapeutics) within the meaning of the Private Securities Litigat
Fulcrum Therapeutics has issued a disclaimer regarding forward-looking statements related to its goals for pociredir, a potential treatment for sickle cell disease. The company emphasizes the associated risks, including regulatory hurdles, clinical trial uncertainties, and market challenges. Pociredir has shown promising data in increasing fetal hemoglobin levels and has received important designations from the FDA. However, the development remains cautious as significant unmet needs and competition in the market persist.
Read more →FULCFulcrum Therapeutics to Present at Upcoming Investor Meetings
Fulcrum Therapeutics will present at the Cantor Fitzgerald and H.C. Wainwright investor conferences. The company focuses on developing treatments for genetically defined rare diseases, with its lead program, pociredir, targeting sickle cell disease. Pociredir has received FDA Fast Track and Orphan Drug designations, showing promise in increasing fetal hemoglobin levels.
Read more →FULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 ― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle ce
Fulcrum Therapeutics reported encouraging results from the 12 mg cohort of its Phase 1b PIONEER trial for pociredir in sickle cell disease, showing a significant increase in fetal hemoglobin and improvements in hemolysis and anemia markers. The treatment appeared well-tolerated among participants, with no serious adverse events. Financially, Fulcrum has $214.1 million in cash to sustain operations through 2028, although the company experienced a significant drop in collaboration revenue and reported a net loss this quarter. Future plans include reporting data from the 20 mg dose cohort by the end of 2025 and advancing programs for inherited aplastic anemias.
Read more →FULCFulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics announced promising results from the 12 mg dose cohort of their Phase 1b PIONEER trial evaluating pociredir for sickle cell disease. The trial demonstrated a significant increase in fetal hemoglobin levels, with 7 out of 16 patients achieving levels over 20%. Key markers of hemolysis improved alongside a well-tolerated safety profile. With reductions in vaso-occlusive crises observed, the findings suggest pociredir may transform treatment for sickle cell patients.
Read more →FULCFulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics is scheduled to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial regarding their investigational drug, pociredir, for sickle cell disease. This presentation will take place via conference call and webcast, with participation from leading experts in the field. Pociredir aims to improve fetal hemoglobin levels by inhibiting EED and has shown initial promise in increasing HbF levels without serious side effects. The drug has been recognized by the FDA with Fast Track and Orphan Drug designations.
Read more →FULCFulcrum Therapeutics to Present at Upcoming Medical Meetings
Fulcrum Therapeutics has announced its upcoming presentations at the 5th Global Congress on Sickle Cell Disease and the 2025 European Hematology Association Congress. They will present findings on Pociredir, a novel oral treatment aimed at increasing fetal hemoglobin in sickle cell disease patients. The drug has shown proof-of-concept with promising early results and has received FDA Fast Track and Orphan Drug Designation. Copies of the presentations will be made available on the company’s website following the congresses.
Read more →FULCFulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference. The event will take place on June 11, 2025, at 8:00 am ET in Miami, FL, and will feature a fireside chat with management. Interested parties can access the webcast online, with a replay available for at least 30 days thereafter. This participation highlights Fulcrum's focus on developing treatments for genetically defined rare diseases.
Read more →FULC▲ +6.7%on this newsshared move
Fulcrum Therapeutics to Participate in Upcoming May Conferences
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming conferences including the H.C. Wainwright BioConnect Investor Conference and the RBC Capital Markets Global Healthcare Conference. This engagement aims to enhance interaction with investors and stakeholders. The company will host a fireside chat, with a replay accessible on their website for 30 days following the event.
Read more →FULC▲ +13.8%on this news· ran to +46% by day 1
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 ― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cel
Fulcrum Therapeutics has completed enrollment in the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir aimed at treating sickle cell disease. The company reported a cash position of $226.6 million as of March 31, 2025, projecting sufficient funds to operate into at least 2027. Clinical data from the trial is anticipated in Q3 2025, along with ongoing developments for treatment of inherited aplastic anemias. Despite a reduction in operational expenses, the net loss remains a point of concern compared to the previous year.
Read more →FULCFulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
Fulcrum Therapeutics, a biopharmaceutical company specializing in rare disease treatments, will announce its first quarter 2025 financial results on May 1, 2025. A conference call and webcast are scheduled for 8:00 a.m. ET, where management will discuss these results and recent corporate developments. Interested individuals can register online to participate in the call.
Read more →FULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 ― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial
Fulcrum Therapeutics reported its fourth quarter and full year results for 2024, highlighting progress in the Phase 1b PIONEER trial for pociredir, aimed at treating sickle cell disease (SCD). The company announced a strong cash position of $241 million, projecting sufficient funding for operations until at least 2027. Despite no collaboration revenue in Q4 2024 and incurring restructuring expenses, Fulcrum remains optimistic about reporting clinical data from the trial in the coming years.
Read more →FULCFulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
Fulcrum Therapeutics, Inc. has scheduled the release of its fourth quarter and full year 2024 financial results on February 25, 2025. Prior to the U.S. financial markets opening, management will host a conference call and webcast at 8:00 a.m. ET to discuss these results. Participants can register for the call and will receive unique access details. An archived replay of the webcast will also be made available following the live event.
Read more →FULCFulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference. Management will engage in a fireside chat scheduled for February 12, 2025, at 1:20 pm ET. The event emphasizes the company's commitment to addressing rare genetic diseases. A playback of the discussion will be available on their website for at least 30 days post-event.
Read more →FULCFulcrum Therapeutics to Participate in Upcoming December Conferences
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in multiple upcoming healthcare conferences, including the Piper Sandler 36th Annual Healthcare Conference and the Citi 2024 Global Healthcare Conference. This participation highlights the company's commitment to engaging with investors and presenting its progress in developing treatments for genetically defined rare diseases. Webcasts of the presentations will be available for public access on their website, indicating a transparent communication strategy.
Read more →FULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 ― Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell dis
Fulcrum Therapeutics reported financial results for Q3 2024, highlighting progress in enrolling patients and site activations for the Phase 1b PIONEER trial of pociredir in sickle cell disease. The company ended the quarter with $257.2 million in cash, expected to sustain operations through at least 2027. Despite a setback in recent trial results for losmapimod, Fulcrum remains focused on advancing pociredir and is on track to report trial data in 2025. The urgency for effective therapies in sickle cell disease has increased due to the withdrawal of OXBRYTA.
Read more →FULCFulcrum Therapeutics to Participate in the Stifel Healthcare Conference
Fulcrum Therapeutics, Inc. announced its participation in the Stifel Healthcare Conference, where management will engage in a fireside chat and one-on-one investor meetings. The event will take place on November 19th in New York City, aiming to increase engagement with potential investors. A webcast of the chat will be made available on the company’s website for those unable to attend live.
Read more →FULCFulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, will release its third quarter 2024 financial results on November 13, 2024. The announcement includes a scheduled conference call and webcast where management will discuss the results and recent corporate updates. This is part of their ongoing commitment to improve the lives of patients with genetically defined rare diseases.
Read more →FULC▼ -61.1%on this newsshared move
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Losmapimod failed to show an improvement in relative surface area (RSA), a m
Fulcrum Therapeutics announced that its Phase 3 REACH trial for losmapimod in patients with facioscapulohumeral muscular dystrophy (FSHD) did not meet its primary endpoint, showing no significant improvement compared to the placebo. As a result, the company has decided to suspend further development of losmapimod. While the drug exhibited a consistent safety profile, secondary endpoints also failed to achieve statistical significance. Fulcrum will focus on other therapeutic programs with the backing of a strong cash position.
Read more →FULC▼ -9.1%on this news
Fulcrum Therapeutics to Participate in Upcoming September Conferences
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in upcoming investor conferences, including the Wells Fargo Healthcare Conference on September 4, 2024, and the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024. This engagement reflects the company's ongoing efforts to connect with investors and promote its focus on developing therapies for genetically defined rare diseases.
Read more →FULCFulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
Fulcrum Therapeutics has appointed Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer. Their expertise is viewed as crucial for advancing losmapimod towards a New Drug Application submission and eventual commercial launch. Kalofonos has a successful history in rare disease drug launches, while Faulds brings extensive regulatory experience from her previous roles. Both leaders are expected to contribute significantly to Fulcrum's transition into a commercial-stage biotechnology company.
Read more →FULC▲ +10.3%on this news
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystr
Fulcrum Therapeutics has announced that it is on track to report topline data from its Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024. The company has entered a collaboration agreement with Sanofi for the development and commercialization of losmapimod outside the U.S., receiving an upfront payment of $80 million. Additionally, Fulcrum reported a net income of $55.4 million for the second quarter of 2024, primarily due to the Sanofi collaboration. The company continues to progress with its other clinical programs, including pociredir for sickle cell disease.
Read more →FULCFulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
Fulcrum Therapeutics, a biopharmaceutical company, has announced its second quarter 2024 financial results will be released on July 31, 2024. A conference call and webcast will take place at 8:00 a.m. ET on the same day to discuss these results and recent corporate developments. Interested individuals are encouraged to register for the call, and an audio webcast will be made available through the company's website post-event.
Read more →FULCFulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
Fulcrum Therapeutics has announced its participation in the 31st Annual FSHD Society International Research Congress, scheduled for June 13-14, 2024, in Denver, Colorado. The company will present critical findings from its Phase 3 REACH trial regarding losmapimod for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Key presentations will cover baseline characteristics of trial participants, disease progression, and the safety and efficacy of losmapimod. These presentations are expected to contribute valuable insights into the management of FSHD.
Read more →FULCFulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
Fulcrum Therapeutics, a biopharmaceutical company specializing in rare diseases, will participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference on June 10, 2024. Management will engage in a fireside chat during the event, which begins at 10:00 a.m. ET. A webcast of the presentation will be made available on the company's website and can be accessed for at least 30 days post-event. This presentation highlights Fulcrum's commitment to advancing its research and development efforts.
Read more →FULCFulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
Fulcrum Therapeutics has entered a collaboration and license agreement with Sanofi for the development and commercialization of losmapimod, an investigational treatment for facioscapulohumeral muscular dystrophy (FSHD). Under the agreement, Sanofi gains exclusive rights outside the U.S., while Fulcrum retains commercialization rights in the U.S. Fulcrum will receive an upfront payment of $80 million and may earn up to $975 million in potential milestones, along with royalties on international sales. This collaboration aims to leverage both companies' resources to advance losmapimod into late-stage clinical trials with a focus on bringing the first approved treatment to FSHD patients.
Read more →FULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercializa
Fulcrum Therapeutics reported its first quarter 2024 financial results, highlighting a new collaboration with Sanofi for the commercialization of losmapimod outside the U.S. The company remains on track to present topline data from its Phase 3 REACH trial for facioscapulohumeral muscular dystrophy (FSHD) in late 2024. Fulcrum's financials showed a net loss of $26.9 million, alongside a reduction in cash position, yet the partnership with Sanofi includes an $80 million upfront payment to support future operations.
Read more →FULCFulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
Fulcrum Therapeutics announced the publication of results from its Phase 2b clinical trial of losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD), showing improvements in functional and structural outcomes, despite the primary endpoint not achieving significant differences. The data, published in The Lancet Neurology, will inform the ongoing Phase 3 clinical trial, with topline results expected in Q4 2024. The drug was well tolerated by participants, and no serious adverse events were observed.
Read more →FULCFulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, will announce its first quarter 2024 financial results on May 13, 2024. Management will host a conference call and webcast at 8:00 a.m. ET to discuss these results and provide updates on corporate developments. The company emphasizes transparency and engagement with investors through the accessibility of the event.
Read more →FULCFulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, will partake in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024. The event aims to engage with stakeholders and share insights related to their development of small molecules for rare diseases. A replay of the presentation will be available on the company's website for at least 30 days post-event.
Read more →FULC▼ -10.9%on this news
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
Fulcrum Therapeutics has appointed Patrick Horn, M.D., Ph.D., as its new Chief Medical Officer, effective immediately. Dr. Horn brings over 20 years of drug development experience, particularly in rare diseases, and is expected to advance Fulcrum's clinical programs, including losmapimod for muscular dystrophy. Alongside interim CMO Iain Fraser, he will oversee the company's medical strategy and execution. Fulcrum is at a crucial juncture as it continues pivotal trials and aims for regulatory submissions.
Read more →FULCFulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation at the Leerink Partners Global Biopharma Conference scheduled for March 13, 2024, in Miami, FL. The company will present a corporate overview and engage in one-on-one meetings with investors. This event highlights Fulcrum's focus on developing therapies for genetically defined rare diseases and provides a platform for new opportunities in funding and collaboration.
Read more →FULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023 ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral
Fulcrum Therapeutics reported its fourth-quarter and full-year financial results for 2023, highlighting progress in its clinical trials. The company is on track to announce topline data from the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024. Additionally, the Phase 1b PIONEER trial of pociredir in sickle cell disease has resumed following a clinical hold. Fulcrum also noted an increase in cash reserves, supporting its ongoing research efforts.
Read more →FULCFulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
Fulcrum Therapeutics, Inc. announced it will release its fourth quarter and full year 2023 financial results on February 27, 2024, before U.S. markets open. A conference call and webcast is scheduled for 8:00 a.m. ET on the same day to discuss the results and provide updates on corporate developments. Participants can register for the call to receive dial-in details, and an archive of the webcast will be available afterward.
Read more →FULCFulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Fulcrum Therapeutics, a biopharmaceutical company dedicated to rare diseases, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. This virtual event is scheduled for February 13, 2024, at 1:20 p.m. ET, and will include one-on-one investor meetings. The presentation aims to provide insights into the company's corporate overview and strategic direction.
Read more →FULC▼ -18.7%on this newsshared move
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The Stifel Healthcare Conference is scheduled for November 14, 2023, followed by the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023. Each conference will feature a fireside chat with management, and live webcasts will be available for investors. This participation highlights the company’s focus on engaging with the investment community regarding its developments in rare diseases.
Read more →FULC▲ +19.5%on this newsshared move
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023 ― Completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSH
Fulcrum Therapeutics has announced key business highlights and financial results for Q3 2023, including the completion of enrollment in the Phase 3 REACH trial of losmapimod for facioscapulohumeral muscular dystrophy. Additionally, the FDA lifted the clinical hold on pociredir for sickle cell disease, allowing for the resumption of the Phase 1b trial. The company's cash position has been strengthened, extending its financial runway through 2026. Fulcrum remains focused on achieving significant clinical milestones in the coming year.
Read more →FULC▲ +8.7%on this news
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
Fulcrum Therapeutics, Inc. announced the upcoming release of its third-quarter 2023 financial results scheduled for November 7, 2023, prior to the opening of U.S. financial markets. The company will also host a conference call and webcast at 8:00 a.m. ET on the same day to discuss these results and provide updates on corporate developments. Interested participants can register online to receive dial-in details for the call, which will also be accessible via an audio webcast on the company's website. A replay of the session will be available afterwards.
Read more →FULCFulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, will participate in the Cantor Fitzgerald Global Healthcare Conference in New York on September 28, 2023. During the event, management will engage in a fireside chat addressing the company's efforts in treating genetically defined rare diseases. The presentation will be accessible through a webcast, with an archived replay available for 90 days on the company’s website.
Read more →FULCFulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics has announced the completion of patient enrollment in the Phase 3 REACH clinical trial for losmapimod, targeting facioscapulohumeral muscular dystrophy (FSHD). A total of 260 patients were enrolled in this pivotal trial across multiple sites in the United States, Canada, and Europe. The study aims to evaluate the efficacy and safety of losmapimod, which has been shown to slow disease progression based on prior trials. The company expects topline data by the end of 2024, moving closer to possible FDA approval.
Read more →FULC▲ +38.5%on this news· ran to +55% by day 1
FTX-6058 f o r S i c k l e C e l l D i s e a s e Program Update F U L C R U M T H E R A P E U T I C S Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securi
Fulcrum Therapeutics is aiming to resume clinical development of FTX-6058, a drug for sickle cell disease, following a hold by the FDA. The phase 1b trial will include several cohorts with varied dosages, and initial data has shown encouraging dose-dependent responses. However, the company faces substantial risks regarding trial enrollment, regulatory approval, and achieving favorable trial results, all amidst leadership changes. The estimated patient population qualifying for the trial is about 7,500 to 10,000 in the U.S.
Read more →FULCFulcrum Therapeutics Appoints Chief Financial Officer
Fulcrum Therapeutics has appointed Alan A. Musso as Chief Financial Officer effective August 7, 2023. Musso brings over 30 years of experience in the life sciences industry, previously serving in senior financial roles at several biopharmaceutical companies. His appointment comes at a crucial time as the company advances its mission to develop therapies for genetically defined rare diseases. However, the company faces challenges, particularly with its FTX-6058 drug, which is under a full clinical hold by the FDA.
Read more →FULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023 ― Screening closed for the Phase 3 REACH pivotal trial of losmapimod in facioscapulohumeral muscular dystroph
Fulcrum Therapeutics announced key developments in its second quarter 2023 report, including the closure of patient screening for the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD). The company expects to reveal topline data in the fourth quarter of 2024. Additionally, they are engaged in resolving an ongoing clinical hold for FTX-6058, which targets sickle cell disease. The financial results exhibited a higher cash position but a decrease in collaboration revenue in comparison to the previous year.
Read more →FULCFulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, will release its second quarter 2023 financial results on August 3, 2023. The company will conduct a conference call and webcast to discuss these results and provide updates on corporate developments. Interested individuals can register for the call to access dial-in details and will also have the option to listen to an archived replay after the event.
Read more →FULCFulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
Fulcrum Therapeutics has entered into an exclusive global license agreement with CAMP4 Therapeutics to develop therapeutic agents for Diamond-Blackfan Anemia (DBA), a rare blood disorder affecting around 5,000 individuals worldwide. This agreement gives Fulcrum full rights to research, develop, and commercialize compounds targeting DBA, which is currently managed with corticosteroids and blood transfusions. Fulcrum will be responsible for all costs related to the project's development, including potential milestone payments to CAMP4. The collaboration aims to innovate treatment options for patients with genetically defined rare diseases.
Read more →FULCFULCRUM THERAPEUTICS, INC.: Please contact the Portnoy Law Firm to recover your losses; June 27, 2023 deadline
Fulcrum Therapeutics, Inc. is facing a lawsuit initiated by the Portnoy Law Firm on behalf of investors who purchased securities within the class period from March 3, 2022, to March 8, 2023. The lawsuit alleges that the company made false statements regarding the safety of FTX-6058, particularly concerning potential hematological malignancies, which led to a full clinical hold from the FDA. As a result, Fulcrum's stock price declined significantly, prompting investors to seek legal recourse to recover losses caused by these alleged corporate misrepresentations.
Read more →FULCFULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is navigating a securities class action lawsuit resulting from alleged false statements about its FTX-6058 drug. The lawsuit covers the period from March 3, 2022, to March 8, 2023, and highlights safety concerns related to hematological malignancies that could impact clinical trials. The FDA has placed a full clinical hold on the drug, leading to a significant drop in the company's stock price. Investors are reminded of the deadline to file a lead plaintiff motion by June 27, 2023.
Read more →FULCFulcrum Therapeutics, Inc. (FULC) Class Action: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Fulcrum Therapeutics, Inc. Class Action Case
Fulcrum Therapeutics, Inc. is facing a class action lawsuit initiated by shareholders who claim the company misled investors about the product candidate FTX-6058. The lawsuit highlights safety concerns regarding preclinical data that suggest risks of hematological malignancies, which could affect FDA approval. Following the announcement of a clinical hold by the FDA, Fulcrum’s stock witnessed a steep decline in value. Shareholders wishing to participate in the class action need to file by June 27, 2023.
Read more →FULC▲ +11.4%on this news
Fulcrum Therapeutics, Inc. (FULC) Equity Alert: Contact Robbins LLP to Learn about the Fulcrum Therapeutics, Inc. Securities Fraud Class Action and Lead Plaintiff Deadline
Fulcrum Therapeutics is facing a securities fraud class action filed by shareholders who claim that the company misled them regarding the safety and viability of its lead product candidate, FTX-6058. The FDA has placed a full clinical hold on the drug, citing preclinical data that raised serious safety concerns, particularly regarding potential hematological malignancies. Following the announcement of the clinical hold, the company's stock price experienced substantial declines. Robbins LLP is offering representation for affected shareholders wishing to participate in the litigation.
Read more →FULC▲ +11.3%on this news
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023 ― Appointed Alex C. Sapir CEO & President, effective July 1st, 2023 ― ― On track to complete
Fulcrum Therapeutics announced significant business highlights and financial results for Q1 2023, including the appointment of Alex C. Sapir as CEO effective July 1, 2023. The company is focused on completing enrollment in the Phase 3 REACH trial of losmapimod for facioscapulohumeral muscular dystrophy (FSHD) within the second half of 2023. Fulcrum continues discussions with the FDA regarding a clinical hold for FTX-6058, which is aimed at treating sickle cell disease. The firm reported a cash position of $297.8 million, indicating a strong financial foundation despite some revenue declines.
Read more →FULC▲ +11.3%on this news
Fulcrum Therapeutics, Inc. (FULC) Class Action Alert: Robbins LLP Urges Investors to Contact the Firm for Information about the Fulcrum Therapeutics, Inc. Securities Class Action
Robbins LLP has issued a class action alert for shareholders of Fulcrum Therapeutics, Inc. (FULC), following claims that the company misled investors about the safety and efficacy of its investigational drug FTX-6058. The legal action was prompted by a recent FDA clinical hold due to potential safety issues involving hematological malignancies. This revelation has led to substantial declines in Fulcrum's stock price, raising concerns among investors about the company’s future prospects and the integrity of its public statements.
Read more →FULC▲ +11.3%on this news
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
Fulcrum Therapeutics has appointed Alex C. Sapir as the new Chief Executive Officer and President, effective July 1, 2023. Mr. Sapir, who previously served as a special advisor to the interim CEO, is recognized for his extensive experience in the biopharmaceutical sector. His leadership is anticipated to propel the company through its next growth phase, and he will also join Fulcrum’s board of directors. The decision underscores Fulcrum's commitment to advancing its pipeline and improving patient outcomes.
Read more →FULC▲ +8.6%on this news
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
Fulcrum Therapeutics, Inc. is set to release its first quarter 2023 financial results on May 15, 2023, before U.S. market opening. The company will host a conference call and webcast at 8:00 a.m. ET to discuss these results and recent corporate developments. Interested individuals can register for the conference call and access a live audio webcast through the company's website.
Read more →FULC▲ +8.6%on this news
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)
Fulcrum Therapeutics, Inc. is currently under scrutiny due to a class action lawsuit following allegations of misleading investors regarding its product FTX-6058. The lawsuit claims that the company concealed safety concerns about the drug, which subsequently led to a full clinical hold imposed by the FDA. Investors experienced a significant loss, with the stock falling more than 56% after the announcement. A deadline for investors to file as lead plaintiffs in the lawsuit has been set for June 27, 2023.
Read more →FULC▲ +6.2%on this newsshared move
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)
Fulcrum Therapeutics, Inc. is facing a securities class action lawsuit after allegations of misleading statements regarding its investigational drug FTX-6058. The lawsuit emerged after the FDA issued a clinical hold on FTX-6058 due to safety concerns related to hematological malignancies. As a result, the company's stock price saw a substantial decline. Investors are encouraged to discuss their rights regarding this matter as legal action progresses.
Read more →FULCFulcrum Therapeutics, Inc. (FULC) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Against Fulcrum Therapeutics, Inc.
A class action has been filed against Fulcrum Therapeutics, Inc. (FULC) by shareholders who claim the company misled them regarding the efficacy and viability of its product, FTX-6058. The lawsuit highlights that Fulcrum did not disclose safety concerns from preclinical data and the likelihood of the FDA imposing a clinical hold on trials. Following the FDA's announcement of a clinical hold due to these safety concerns, Fulcrum's stock price has notably declined. Investors are now considering their options for participating in the legal proceedings against the company.
Read more →FULC▲ +8.8%on this newsshared move
Fulcrum Therapeutics, Inc. (FULC) Class Action Lawsuit Filed by Holzer & Holzer, LLC on Behalf of Investors - Nationally Ranked Investors’ Rights Firm Encourages Investors With Significant Losses to Contact the Firm
Holzer & Holzer, LLC has initiated a class action lawsuit against Fulcrum Therapeutics, alleging that the company made materially false or misleading statements regarding its drug candidate FTX-6058. The lawsuit claims that preclinical data indicated safety concerns that could lead to the FDA placing a clinical hold on the drug's studies. Investors who purchased shares of Fulcrum between March 3, 2022, and March 8, 2023, and experienced losses are encouraged to seek legal counsel. The deadline to be appointed as lead plaintiff in this case is June 27, 2023.
Read more →FULC▼ -7.6%on this newsshared move
Fulcrum Therapeutics Announces CFO Resignation
Fulcrum Therapeutics announced the resignation of CFO Esther Rajavelu, effective April 21, 2023. Rajavelu will transition to a consulting role to assist in financial operations. The company has expressed confidence in its financial position, citing a cash runway extending into mid-2025 and upcoming initiatives. However, concerns remain about the implications of executive turnover and the clinical hold on the FTX-6058 program.
Read more →FULC▼ -23%on this news· ran to -37% by day 3shared move
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022 ― Company is working to address clinical hold on the Investigational New Drug application f
Fulcrum Therapeutics provided a business update alongside its Q4 and full-year 2022 financial results, reporting significant developments regarding its investigational drug FTX-6058 for sickle cell disease. The FDA has placed this drug on clinical hold due to safety concerns related to hematological malignancies associated with other drugs in its class, pausing its Phase 1b trial. Despite these challenges, Fulcrum remains committed to addressing the clinical hold and is on track for the Phase 3 REACH trial enrollment of losmapimod in muscular dystrophy patients. The company successfully raised $117.3 million through a public offering, extending its financial runway into mid-2025.
Read more →FULCFulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, is set to release its fourth quarter and full year 2022 financial results on March 9, 2023. A conference call and webcast will follow at 8:00 a.m. ET to discuss these results and update on recent corporate developments. The event highlights the company's ongoing commitment to transparency and engagement with investors.
Read more →FULC▼ -56.1%on this news
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
Fulcrum Therapeutics has announced a full clinical hold on its drug FTX-6058, which is being studied for the treatment of sickle cell disease. This decision follows concerns raised by the FDA regarding preclinical data associated with the drug. While Fulcrum plans to work closely with the Agency to address these issues and remains confident in FTX-6058's therapeutic potential, the hold requires the suspension of dosing in the ongoing Phase 1b trial. The company acknowledges the significance of patient safety as it navigates this process.
Read more →FULCFulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the upcoming SVB Securities Global Biopharma Conference on February 15, 2023. The presentation is set to be virtual, allowing a wide audience to access it. The event presents an opportunity for Fulcrum to highlight its focus on genetically defined rare diseases and potentially attract further investor interest.
Read more →FULCFulcrum Therapeutics Announces Proposed Public Offering of Common Stock
Fulcrum Therapeutics has announced a proposed public offering of $100 million in common stock. The offering is subject to market and other conditions, which introduces uncertainty regarding its completion and terms. Goldman Sachs, SVB Securities, and Piper Sandler are managing the offering. Fulcrum aims to fund its initiatives to treat genetically defined rare diseases but faces various risks that could impact the offering's success.
Read more →FULCFulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Fulcrum Therapeutics has announced the pricing of an upsized public offering of 9,615,384 shares of common stock at $13.00 each, aiming to raise approximately $125 million before expenses. The company has granted underwriters a 30-day option to purchase an additional 1,442,307 shares. The offering is set to close around January 20, 2023, provided customary conditions are met. Fulcrum is focused on treating genetically defined rare diseases with two lead programs currently in clinical development.
Read more →FULCFulcrum Therapeutics Announces CEO Transition
Fulcrum Therapeutics has announced that Robert J. Gould, Ph.D., has been appointed as interim CEO following the departure of Bryan Stuart. Gould, who is a founding member and former CEO, brings a wealth of experience to the role as the company seeks a permanent CEO. Under his leadership, Fulcrum aims to advance its clinical programs, including FTX-6058 for sickle cell disease and losmapimod for muscular dystrophy disorders. The transition is expected to maintain continuity in Fulcrum's strategic priorities and mission.
Read more →FULCFulcrum Therapeutics Provides Business Update and 2023 Outlook FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 Completed enrollment in 6 mg and 2 mg dose cohorts of the Pha
Fulcrum Therapeutics has provided a business update and outlook for 2023, highlighting the Fast Track designation granted for FTX-6058, an oral HbF inducer for sickle cell disease. The company completed enrollment in the 6 mg and 2 mg cohorts of the Phase 1b trial and is gathering additional data for the 12 mg dose. Additionally, interim CEO Robert J. Gould has taken over following the departure of Bryan Stuart. Fulcrum is also planning to complete enrollment in the Phase 3 REACH trial for losmapimod targeting facioscapulohumeral muscular dystrophy by the end of the year.
Read more →FULCFulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virt
Read more →FULC▲ +15%on this news· ran to +27% by day 3shared move
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results – Selected 12mg as the dose for next cohort in the Phase 1b trial of FTX-6058 in sickle cell disease (SCD) –
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results Selected 12mg as the dose for next cohort in the Phase 1b trial of FTX-6058 in sickle cell disease (SCD) Presented 96-week data from the Phase 2 ReDUX4 trial open label extension
Read more →FULCFulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
— Santiago Arroyo, M.D., Ph.D. joined as CMO on November 7, 2022 — — Jeff W. Jacobs, Ph.D. to join as CSO on December 1, 2022 — CAMBRIDGE, Mass. –, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused o
Read more →FULCFulcrum Therapeutics to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2022 financial resul
Read more →FULCFulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
- 96-week findings support losmapimod as a disease-modifying therapy for FSHD - U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 - Industry Symposium on October 12, 2022, at 4:30pm EDT CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Fulcrum Th
Read more →FULC▼ -8.1%on this newsshared move
Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the fo
Read more →FULC▼ -6.9%on this news
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offe
Read more →FULC▼ -6.9%on this news
Fulcrum Therapeutics to Participate at the Upcoming Stifel 2022 Biotech Summer Summit
CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fires
Read more →FULCFulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update – Presented initial data from Phase 1b trial in sickle cell disease (SCD), which demonstrate rapid and robust increases in h
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results Presented initial data from Phase 1b trial in sickle cell disease (SCD), which demonstrate rapid and robust increases in hemoglobin F (HbF); supports proof-of-concept that FTX-6058 is a novel oral HbF inducer
Read more →FULC▲ +13.6%on this news· ran to +30% by day 1
Fulcrum Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2022 financial resu
Read more →FULCFulcrum Therapeutics Announces Departure of Chief Medical Officer
CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Chief Medical Officer, Christopher Mor
Read more →FULC▲ +11.4%on this news
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease – – Losmapimod is an oral small molecule that has the potential to be the first therapy to treat FSHD, the second most common form of muscular dystrophy – – U.S. Food and Drug Admin
Read more →FULC▼ -39.2%on this news
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint - Supports proof-of-concept that FTX-6058 is a novel oral HbF inducer - FTX-6058 was generally well tolerated; no serious treatment emergent adv
Read more →FULC▲ +5.1%on this news· ran to +21% by day 3
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability, pharmacokinetics, and other pharmacodynamic measures from the ongoing 6 mg dose cohort of FTX-6058 in adults with sickle cell disease (SCD
Read more →FULC▼ -11.2%on this newsshared move
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results – Initial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress  
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results Initial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress Phase 3 REACH trial of losmapimod in FSHD expected to begin in 2Q 2022
Read more →FULC▼ -7.3%on this news· ran to -21% by day 3shared move
Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fires
Read more →FULCFulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2022 financial resul
Read more →FULCFulcrum Therapeutics Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting
Presentations highlight potential of losmapimod to slow or stop progression of FSHD Company on track to initiate Phase 3 REACH trial in 2Q 2022 CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical com
Read more →FULCFulcrum Therapeutics to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial Live webcast March 24, 2022 at 10:00am ET CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company
Read more →FULCFulcrum Therapeutics Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific Conference
RWS has been correlated with ability to perform activities of daily living and maintain independence Losmapimod shown to improve or preserve function as measured by RWS in two Phase 2 studies, supporting RWS as the primary endpoint in Phase 3 REACH trial Company on track to ini
Read more →FULC▲ +5.4%on this news· ran to +38% by day 3
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results – Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022 On track to report initial data from Phase 1b trial with FTX-6
Read more →FULC▲ +5.4%on this news· ran to +38% by day 3
Fulcrum Therapeutics Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Reachable Workspace (RWS) primary endpoint based on discussions with FDA and EU regulatory agencies Trial expected to begin in 2Q 2022 Potential first-to-market therapy for FSHD Fulcrum to host virtual Key Opinion Leader webcast on FSHD on March 24 at 10:00am ET CAMBRIDGE, Ma
Read more →FULC▲ +5.8%on this news
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2021
Read more →FULCFulcrum Therapeutics to Participate in 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fires
Read more →FULCFulcrum Therapeutics Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; Initial data expecte
Fulcrum Therapeutics Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; Initial data expected in 2Q 2022 Submitted IND for FTX-6058 to support initia
Read more →FULC▼ -7.3%on this newsshared move
Fulcrum Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan Stuart, President and Chief Exec
Read more →FULCFulcrum Therapeutics Appoints Esther Rajavelu as Chief Financial Officer
Fulcrum Therapeutics Appoints Esther Rajavelu as Chief Financial Officer CAMBRIDGE, Mass., January 4, 2022 Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, t
Read more →FULCFulcrum Therapeutics Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure Continues to be well-tolerated at higher doses with no serious adverse events observed to date N
Read more →FULCFulcrum Therapeutics Appoints Sonja L. Banks to its Board of Directors
Fulcrum Therapeutics Appoints Sonja L. Banks to its Board of Directors CAMBRIDGE, Mass., November 17, 2021 Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, t
Read more →FULCFulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results - On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease - -
Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results - On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease - - Losmapimod update planned for Q1 2022 - - Raised $144.2
Read more →FULCFulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in th
Read more →FULCFulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2021 financial resul
Read more →FULCFulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of an inducement award outside of
Read more →FULCFulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society
– Presentations highlight progress in the development of losmapimod for FSHD – CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Read more →FULC▼ -5.3%on this newsshared move
Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Mel Hayes as Chief Comm
Read more →FULCFulcrum Therapeutics™ to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in t
Read more →FULC▼ -5.2%on this news
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its previously announced underwr
Read more →FULC▲ +7.6%on this newsshared move
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering CAMBRIDGE, Mass., August 11, 2021 Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, toda
Read more →FULC▲ +125.3%on this news· ran to +175% by day 3shared move
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results - Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell d
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results - Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biolo
Read more →FULC▲ +125.3%on this news· ran to +175% by day 3shared move
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
Achieved dose proportional pharmacodynamic changes in HBG mRNA and F-reticulocytes in whole blood Mean 4.5-fold induction in HBG mRNA at 10mg after 14 days of once-daily dosing Mean 4.2-fold increase in F-reticulocytes at 10mg after 14 days of once-daily dosing Achieved maxima
Read more →FULCFulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET
CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2021 financial resu
Read more →FULCFulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function
Primary endpoint, change in DUX4-driven gene expression which was included as an experimental biomarker, was not met Losmapimod showed statistically significant* (p<0.05) and clinically relevant benefit across multiple structural, functional and patient reported endpoints Decrea
Read more →FULCFulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)
CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the 28th Annual F
Read more →FULCFulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the U.S. Food and Drug Administration (
Read more →FULCFulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will present a corporate ove
Read more →FULCFulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer
CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced Christopher J. Morabito, M.D. has been appoi
Read more →FULCFulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results - On track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) at v
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results - On track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) at virtual FSHD International Research Congress in June 2021 -
Read more →FULCFulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2021 financial resu
Read more →FULCFulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today presented the medicinal chemistry strategy for FTX-6
Read more →FULCFulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development CAMBRIDGE, Mass., March 24, 2021 Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically define
Read more →FULCFulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
– Demonstrated Whole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with FSHD clinical endpoints – – Demonstrated potential of FSHD-TUG and Emerald in-home assessments as accurate, low-burden clinical assessments of mobil
Read more →FULCFulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021 On track to report resu
Read more →FULCFulcrum Therapeutics Recognizes Rare Disease Day 2021
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the company’s recognition of Rare Disease D
Read more →FULCFulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2020
Read more →FULCFulcrum Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the fol
Read more →FULCFulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Christopher Moxham, Ph.D., has been pr
Read more →FULCFulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fires
Read more →FULCFulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
Event will review the company’s novel approach to inducing fetal hemoglobin Live webcast on December 15, 2020 at 8:30am ET CAMBRIDGE, Mass., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improv
Read more →FULCFulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that preclinical data with FTX-6058 for the
Read more →FULCFulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results - ReDUX4 trial progressing; full data with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) expected in 2Q 2021
Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results - ReDUX4 trial progressing; full data with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) expected in 2Q 2021 - - On track to begin dosing Phase 1 trial with FTX-6058
Read more →FULCFulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters on the com
Read more →FULCFulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8:00 a.m. ET
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2020 financial resul
Read more →FULCFulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Investigational New Drug applicat
Read more →FULCFulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters on the com
Read more →FULCFulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting
- Fetal Hemoglobin expression in human cellular models increased up to ~30% by FTX-6058 for the potential treatment of sickle-cell disease - Company plans to initiate Phase 1 trial in healthy volunteers by year-end - Non-provisional composition of matter patent application cove
Read more →FULCFulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results - Conference call scheduled for 8:00 a.m. ET today
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results - Conference call scheduled for 8:00 a.m. ET today - CAMBRIDGE, Mass. - August 11, 2020 - Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company foc
Read more →FULCFulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
Reduction in DUX4-driven gene expression observed in biopsies with highest baseline levels of DUX4-driven gene expression Topline data on-track for Q1 2021 with full data in Q2 2021 Company to review clinical data on second quarter earnings call today at 8:00am ET CAMBRIDGE, M
Read more →FULCFulcrum Therapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 11, 2020 at 8:00 a.m. ET
CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2020 financial resu
Read more →FULCFulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients
CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it received early notification from th
Read more →FULCFulcrum Therapeutics Completes $68.5 Million Private Placement
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced the closing of a $68.5 million private placement pursuant to a securities purchase agreement with a group of institutional investors and accredited investors. The privat
Read more →FULCFulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19 Investigational New Drug (IND) application submitted; Company preparing to initiate Phase 3 trial ReDUX4 interim analysis in facioscapulohum
Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for Investigational New Drug (IND) application submitted; Company preparing to initiate Phase 3 trial ReDUX4 interim analysis in facioscapulohumeral dystrophy (FSHD) on track for Q3 2020 readout; FTX-6058 Phase
Read more →FULCFulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
CAMBRIDGE, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the 2020 American
Read more →FULCFulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results - Conference call scheduled for 8:00 a.m. ET today
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results - Conference call scheduled for 8:00 a.m. ET today - CAMBRIDGE, Mass. - May 13, 2020 - Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused
Read more →FULCFulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a firesi
Read more →FULCFulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8:00 a.m. ET
CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2020 financial result
Read more →FULCFulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease
CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it is on track for submission of an Invest
Read more →FULCFulcrum Therapeutics Provides Business Update on Impact of COVID-19
CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update in the context of the dev
Read more →FULCFulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
– Losmapimod achieves target engagement in muscle – – Oral presentation at Virtual Muscular Dystrophy Association (MDA) Clinical and Scientific Conference highlights safety, tolerability and pharmacokinetics of losmapimod – CAMBRIDGE, Mass., March 24, 2020 (GLOBE NEWSWIRE) -- F
Read more →FULCFulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results - Conference call scheduled for 8:00 a.m. ET today
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results - Conference call scheduled for 8:00 a.m. ET today - CAMBRIDGE, Mass. - March 5, 2020 - Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical
Read more →FULCFulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the company’s support for Rare Disease Day
Read more →FULCFulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Topline data on track for 3Q 2020 Dosing Initiated in ReDUX4 Open Label Extension CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with geneticall
Read more →FULCFulcrum Therapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Thursday, March 5, 2020 at 8:00 a.m. ET
CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2019
Read more →FULCFulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio
CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the United States Food and Drug Admini
Read more →FULCFulcrum Therapeutics Appoints Katina Dorton to its Board of Directors
Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors CAMBRIDGE, Mass., Jan. 6, 2020 Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today an
Read more →FULCFulcrum Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that members of the management team will pr
Read more →FULCFulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights - Announced preliminary results of a Phase 1 clinical trial of losmapimod in FSHD patients - - Initiated IND-enabling studi
Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights - Announced preliminary results of a Phase 1 clinical trial of losmapimod in FSHD patients - - Initiated IND-enabling studies for FTX-6058 for the potential treatment of sickle cel
Read more →FULCFulcrum Therapeutics to Present at the Stifel 2019 Healthcare Conference
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that members of the management team will pr
Read more →FULCFulcrum Therapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a live conference call an
Read more →FULCFulcrum Therapeutics to Host Key Opinion Leader Breakfast Symposium on Facioscapulohumeral Dystrophy (FSHD), on November 7, 2019
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a key opinion leader (KOL
Read more →FULCFulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target engagement of losmapimod in patients with facioscapulohume
Read more →FULCFulcrum Therapeutics Announces Multiple Presentations of Losmapimod Data at World Muscle Society Meeting
Oral presentation to highlight Phase 1 data on safety, tolerability and target engagement of losmapimod in treatment of FSHD Company also announces updated preclinical data on FTX-6058 for potential treatment of sickle cell disease; FTX-6058 showed an increase in HbF levels to ~
Read more →FULCFulcrum Therapeutics Appoints Pamela Strode, Seasoned Industry Executive, to Lead Regulatory Affairs Team
Strode brings experience leading regulatory affairs and quality assurance across multiple therapeutic areas, including rare diseases with high unmet need CAMBRIDGE, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceu
Read more →FULCFulcrum Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that members of the management team will p
Read more →FULCFulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights Completed initial public offering, raising $72.0 million in gross proceeds Initiated ReDUX4, a Phase 2b clinical trial of
Fulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights Completed initial public offering, raising $72.0 million in gross proceeds Initiated ReDUX4, a Phase 2b clinical trial of losmapimod in FSHD Initiated a Phase 2 open label clinic
Read more →FULCFulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it has initiated ReDUX4, a Phase 2b clinica
Read more →FULCFulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference
CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare
Read more →FULCFulcrum Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initi
Read more →Competitive Position
How FULC ranks across every disease it competes inCompetitive Position is a premium feature
See how FULC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial